Therapeutic monoclonal antibodies are the fastest growing class of therapeutics for the treatment of various cancers and inflammatory disorders. The Fc region of human IgG antibodies interacts with multiple Fcγ receptor (FcγR) and complement proteins and mediates immune effector functions, which are important for many therapeutic applications, e.g. elimination of targeted cells via antibody-dependent cellular-cytotoxicity (ADCC), -phagocytosis (ADCP) or complement-dependent cytotoxicity (CDC).
To date, therapeutic IgG antibodies (either approved
or in clinical development) belong to the IgG1, IgG2 or IgG4 subclasses. Each
IgG isotype has a distinct binding affinity to the various FcγRs, which are expressed differently on immune
cells.
In cancer immunotherapy, some IgG1 antibodies (eg
ipilimumab) rely on the Fc-mediated immune effector function, dependent
cellular cytotoxicity (ADCC), as the major mode of action to deplete tumor
cells.
It is well-known that this effector function is
modulated by the N-linked glycosylation (N297) in the Fc region of
the antibody.
In fact, if the N297A mutation is able to reduced FcγR-binding and abolish ADCC activity on the other hand, the absence of core fucose on the Fc N-glycan has been shown to increase IgG1 Fc binding affinity to the FcγRIIIa present on immune effector cells such as natural killer cells and lead to enhanced ADCC activity.
Media
supplementation with 200 µM of 2F-Peracetyl-Fucose allow to produce
low fucosilated mabs with transient transfection in Expi293 or ExpiCHO cells) just
before cell transfection (as reported on Chakraborty et.al for the Expi293 cells) allow to produce a mab with low fucosilation level (as
reported in Fig1) and enhanced ADCC activity.
n.b: The results of ELISA assay on mabs produced from Expi293 and ExpiCHO seem to suggest that the ExpiCHO show a decreased fucosilation level respect than Expi293 also in absence of the 2F paracetyl fucose.
Preparation of 2F-Peracetyl-Fucose
stock solution:
2F-Peracetyl-Fucose is supplied as powder (10mg). It
can be directly resuspended in the glass bottle with 1mM DMSO to obtain a 34.2mM
stock solution (171X) that could be stored at -20°C.
584µl of 34.2mM of 2F-Peracetyl-Fucose were
added to 100 ml of cells just before the transient transfection with
Expifectamines
Prons:
Very Simple!!
Concerns:
Expensive: Cost of 2F-Peracetyl-Fucose: ~ 1000euro/liter of transfection make this approach feasible
only for small lab scale productions